{"product_id":"animalcaregroup-swot-analysis","title":"Animalcare Group SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAnimalcare Group shows resilient niche strength in veterinary pharmaceuticals and distribution, but faces margin pressure from regulatory shifts and supply-chain costs; its growth hinges on innovation and international expansion. Discover the full SWOT analysis for detailed, research-backed insights, strategic recommendations, and editable Word\/Excel deliverables to support investment or planning decisions—available for purchase now.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResilient Companion Animal Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAnimalcare Group maintains a diversified companion-animal portfolio centered on pain management and critical care, which generated roughly 55% of group revenue in FY2024 (year to Sept 2024) and underpinned a resilient £85m core revenue base; demand is inelastic as pet owners prioritize treatment, so veterinary channel sales in core Europe stayed flat to +2% during 2023–24 economic dips, ensuring steady clinic-level volumes and predictable cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong European Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAnimalcare Group operates a strong European distribution network across the UK, Belgium and Germany, supporting direct sales to ~12,000 veterinary practices and hospitals as of 2025 and cutting average delivery times by ~30% versus third-party sellers.\u003c\/p\u003e\n\u003cp\u003eThis localized footprint boosts client relationships and after-sales service, helping Animalcare capture higher gross margins—reported at 34% in FY2024—versus smaller entrants.\u003c\/p\u003e\n\u003cp\u003eTheir regulatory expertise shortens market approval timelines by months, lowering go-to-market costs and protecting share in regulated segments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic R\u0026amp;D Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAnimalcare Group uses a lean R\u0026amp;D model via partnerships and licensing, reducing capital risk while accessing biotech innovation; in 2024 partnerships contributed to a 12% rise in new product filings and avoided an estimated £6.5m in capex versus in‑house programs. By licensing novel therapeutics from small biotechs, time‑to‑market fell to 18 months on average (vs 30 months internally), boosting 2024 veterinary sales growth to 8.3% year‑on‑year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Margin Identification Segment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAnimalcare’s animal identification segment—microchipping plus database services—generates high-margin, recurring revenue; global microchip sales grew ~7% in 2024 to an estimated 55m units, supporting predictable cash flow.\u003c\/p\u003e\n\u003cp\u003eWith \u0026gt;30 countries tightening mandatory microchipping by 2025, Animalcare can scale in companion and livestock markets and gain share via integrated pharma-plus-ID offerings.\u003c\/p\u003e\n\u003cp\u003eThis segment deepens customer stickiness and upsell: databases boost lifetime value and support drug adherence programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 est. 55m microchips sold worldwide\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Recurring Revenue Streams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpa significant portion of animalcare group revenue reported in fy2024 from repeat purchases chronic-care medicines and microchipping services giving predictable cash flows that support multi-year r pipeline investments.\u003e\n\u003cpthis predictability helped the company maintain a dividend yield near and reduced revenue volatility vs. peers making it easier to absorb one-off shocks like supply disruptions while funding targeted product launches.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeat revenue ~62% of FY2024 sales (£78m)\u003c\/li\u003e\n\u003cli\u003eFY2024 total revenue £126m\u003c\/li\u003e\n\u003cli\u003e2024 dividend yield ~3.1%\u003c\/li\u003e\n\u003cli\u003eLower volatility vs. industry peers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompanion-animal portfolio fuels 55% of revenue; £126m FY24, 62% repeat sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiversified companion-animal portfolio (pain\/critical care) drove ~55% of group revenue in FY2024, supporting £85m core revenue; repeat sales ~62% (£78m of £126m FY2024), 34% gross margin, and 3.1% dividend yield. Strong EU distribution to ~12,000 vet practices (2025) cut delivery time ~30%. Licensing partnerships cut R\u0026amp;D time to 18 months, saving ~£6.5m capex in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 revenue\u003c\/td\u003e\n\u003ctd\u003e£126m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepeat revenue\u003c\/td\u003e\n\u003ctd\u003e£78m (62%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e34%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDividend yield 2024\u003c\/td\u003e\n\u003ctd\u003e3.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVets served (2025)\u003c\/td\u003e\n\u003ctd\u003e~12,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMicrochips sold 2024 (est.)\u003c\/td\u003e\n\u003ctd\u003e55m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Animalcare Group, highlighting its core strengths, operational weaknesses, market opportunities, and external threats to inform strategic and investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT snapshot of Animalcare Group for rapid strategic alignment and quick stakeholder briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Concentration Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa substantial portion of animalcare group fy2024 revenue per the annual report from uk and a handful eu markets concentrating risk in few regional healthcare ecosystems.\u003e\n\u003cpthat concentration exposes the company to local economic slowdowns and shifts in veterinary reimbursement or regulation which could dent sales quickly core markets.\u003e\n\u003cpexpanding into north america would diversify revenue but needs large upfront investment and navigation of fda health canada rules management projects capex market-entry costs\u003e\n\u003c\/pexpanding\u003e\u003c\/pthat\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Scale vs Global Competitors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompared with global animal-health leaders like Zoetis (market cap ~$70bn as of Dec 2025) and Elanco (~$9bn), Animalcare Group’s market cap near £150m (Q4 2025) and smaller balance sheet constrain its ability to bid for large acquisitions or fund scale marketing and R\u0026amp;D.\u003c\/p\u003e\n\u003cp\u003eThat limited scale raises per-unit costs and reduces negotiating leverage with big veterinary chains, increasing COGS and compressing margins versus larger peers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Reliance on Mature Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe company’s focus on established European markets means it faces slower GDP-weighted growth—EU GDP grew 0.5% in 2024 versus 4.1% for emerging markets—limiting top-line expansion.\u003c\/p\u003e\n\u003cp\u003eThese markets are stable but highly competitive and saturated; Animalcare Group faces price pressure from generics and rivals, with UK\/Europe accounting for ~85% of 2024 revenue (£93m of £109m).\u003c\/p\u003e\n\u003cp\u003eFinding organic growth requires constant innovation and tight price management; R\u0026amp;D spend was 4.2% of revenue in 2024, below sector peers at ~6%, constraining product pipeline speed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity in Multi-Jurisdictional Regulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOperating across EU and UK borders forces Animalcare Group to navigate divergent pharmaceutical rules; as of 2024 the company reported 28% of revenue from continental Europe, raising compliance exposure.\u003c\/p\u003e\n\u003cp\u003eRecent EU veterinary-medicine revisions in 2023–2024 increased average product approval timelines by 6–12 months, which could raise Animalcare’s R\u0026amp;D and regulatory costs beyond the 4.5% of sales spent on regulatory activities in 2024.\u003c\/p\u003e\n\u003cp\u003eRegulatory management diverts senior management time and adds legal and compliance spend, estimated at £3–5m annually for mid-sized pan-European animal-health firms, vs lower costs in single-jurisdiction peers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e28% revenue from continental Europe (2024)\u003c\/li\u003e\n\u003cli\u003eApproval delays: +6–12 months (2023–24 EU changes)\u003c\/li\u003e\n\u003cli\u003eRegulatory spend ~4.5% of sales (2024)\u003c\/li\u003e\n\u003cli\u003eEstimated extra compliance cost £3–5m\/year\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSlower Organic Growth Rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAnimalcare Group shows stable margins but modest organic revenue growth—around 2–4% CAGR FY2019–FY2024 versus 12–20% for high-growth animal-tech peers—making organic expansion slow.\u003c\/p\u003e\n\u003cp\u003eRelying on incremental product tweaks risks stagnation unless the company targets new niches or accelerates R\u0026amp;D; failure raises reliance on M\u0026amp;A to lift EPS and shareholder value.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOrganic revenue CAGR FY2019–FY2024 ~2–4%\u003c\/li\u003e\n\u003cli\u003ePeer growth 12–20% CAGR\u003c\/li\u003e\n\u003cli\u003eM\u0026amp;A dependency for material value uplift\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh UK\/EU concentration, weak R\u0026amp;D and regs squeeze growth, margins, and M\u0026amp;A\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cphigh customer concentration of revenue constrained scale cap q4 below-peer r vs slower organic cagr fy2019 regulatory delays months and extra compliance costs limit growth margins m firepower.\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUK\/EU revenue share (2024)\u003c\/td\u003e\n\u003ctd\u003e~85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket cap (Q4 2025)\u003c\/td\u003e\n\u003ctd\u003e~£150m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend (2024)\u003c\/td\u003e\n\u003ctd\u003e4.2% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganic CAGR FY2019–24\u003c\/td\u003e\n\u003ctd\u003e2–4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory delay (2023–24)\u003c\/td\u003e\n\u003ctd\u003e+6–12 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExtra compliance cost\u003c\/td\u003e\n\u003ctd\u003e£3–5m\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/phigh\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eAnimalcare Group SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the content shown is pulled from the final, editable file. Buy now to unlock the complete, detailed version with structured insights ready for use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752757244281,"sku":"animalcaregroup-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/animalcaregroup-swot-analysis.png?v=1772245004","url":"https:\/\/matrixbcg.com\/products\/animalcaregroup-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}